Truist Financial Initiates Coverage on Septerna (NASDAQ:SEPN)

Stock analysts at Truist Financial assumed coverage on shares of Septerna (NASDAQ:SEPN) in a report issued on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $34.00 price target on the stock. Truist Financial’s target price indicates a potential upside of 29.62% from the company’s current price.

A number of other equities analysts have also issued reports on SEPN. Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $18.00 to $28.00 in a research report on Friday, November 14th. HC Wainwright increased their price target on shares of Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Wall Street Zen upgraded shares of Septerna from a “sell” rating to a “buy” rating in a report on Sunday, November 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Septerna in a research report on Friday, September 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.25.

Septerna Stock Performance

NASDAQ SEPN opened at $26.23 on Monday. The stock has a 50-day simple moving average of $23.46 and a 200 day simple moving average of $16.59. Septerna has a twelve month low of $4.17 and a twelve month high of $29.74. The stock has a market capitalization of $1.17 billion, a PE ratio of -17.37 and a beta of 3.80.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The business had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. As a group, equities research analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Insider Activity

In other news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the transaction, the senior vice president owned 92,911 shares in the company, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. Deutsche Bank AG boosted its position in Septerna by 53.3% in the first quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock valued at $92,000 after buying an additional 5,549 shares in the last quarter. Swiss National Bank bought a new position in shares of Septerna in the first quarter valued at approximately $174,000. Nuveen LLC acquired a new position in shares of Septerna in the 1st quarter worth approximately $139,000. Stoneridge Investment Partners LLC bought a new stake in shares of Septerna during the first quarter worth $107,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Septerna during the first quarter worth $394,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.